Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate
Executive Summary
CDER Director Woodcock grants accelerated approval after FDA Commissioner Califf refuses to overturn her finding that the drug's effect on dystrophin is reasonably likely to predict clinical benefit in Duchenne muscular dystrophy.
You may also be interested in...
Stockwatch: Lax Approval Requirements Yield Blockbusters That Don’t Work
With the backdrop of Biogen’s BLA filing, and the FDA’s expected response for aducanumab in Alzheimer’s disease in 2020, the link between efficacy and approval seems to have broken. Conditional FDA approvals can’t help when the conditions are ignored.
Court Rules More Trial Data Must Be Posted On ClinicalTrials.gov
Plaintiff Peter Lurie, former US FDA associate commissioner, expects results of hundreds of clinical trials of approved medical products will become available under ruling against HHS.
Court Rules More Trial Data Must Be Posted On ClinicalTrials.gov
Plaintiff Peter Lurie, former US FDA associate commissioner, expects results of hundreds of clinical trials of approved drugs will become available under ruling against HHS; co-plaintiff sought eteplirsen study data.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: